756 related articles for article (PubMed ID: 33222462)
41. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
[TBL] [Abstract][Full Text] [Related]
42. High-dose Intravenous Vitamin C in Early Stages of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Double-blind, Randomized, Controlled Clinical Trial.
Labbani-Motlagh Z; Amini S; Aliannejad R; Sadeghi A; Shafiee G; Heshmat R; Jafary M; Talaschian M; Akhtari M; Jamshidi A; Mahmoudi M; Sadeghi K
J Res Pharm Pract; 2022; 11(2):64-72. PubMed ID: 36798102
[TBL] [Abstract][Full Text] [Related]
43. [Evaluation of clinical value of Xuebijing combined with human immunoglobulin in severe and critically ill patients with coronavirus disease 2019].
Chen L; Zhang A; Li Q; Cui Y; Yuan G
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Apr; 33(4):399-404. PubMed ID: 34053480
[TBL] [Abstract][Full Text] [Related]
44. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
[TBL] [Abstract][Full Text] [Related]
45. A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.
McEvoy NL; Clarke JL; Mc Elvaney OJ; Mc Elvaney OF; Boland F; Hyland D; Geoghegan P; Donnelly K; Friel O; Cullen A; Collins AM; Fraughen D; Martin-Loeches I; Hennessy M; Laffey JG; Mc Elvaney NG; Curley GF
Trials; 2021 Apr; 22(1):288. PubMed ID: 33874981
[TBL] [Abstract][Full Text] [Related]
46. Tocilizumab for the Critically Ill With Severe COVID-19: A Community Hospital Case Series.
McKenzie MG; Lee YM; Mathew J; Anderson M; Vo AT; Akinyele S; Narayanan M
J Pharm Pract; 2022 Aug; 35(4):587-592. PubMed ID: 33736526
[TBL] [Abstract][Full Text] [Related]
47. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).
Urwyler P; Charitos P; Moser S; Heijnen IAFM; Trendelenburg M; Thoma R; Sumer J; Camacho-Ortiz A; Bacci MR; Huber LC; Stüssi-Helbling M; Albrich WC; Sendi P; Osthoff M
Trials; 2021 Jan; 22(1):1. PubMed ID: 33397449
[TBL] [Abstract][Full Text] [Related]
48. Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial.
Murai IH; Fernandes AL; Sales LP; Pinto AJ; Goessler KF; Duran CSC; Silva CBR; Franco AS; Macedo MB; Dalmolin HHH; Baggio J; Balbi GGM; Reis BZ; Antonangelo L; Caparbo VF; Gualano B; Pereira RMR
JAMA; 2021 Mar; 325(11):1053-1060. PubMed ID: 33595634
[TBL] [Abstract][Full Text] [Related]
49. Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients.
Wang Z; Chen J; Zhu C; Liu L; Qi T; Shen Y; Zhang Y; Xu L; Li T; Qian Z; Steinhart CR; Lu H
Front Immunol; 2021; 12():568789. PubMed ID: 34149679
[TBL] [Abstract][Full Text] [Related]
50. Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial.
Bosteels C; Maes B; Van Damme K; De Leeuw E; Declercq J; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):491. PubMed ID: 32503663
[TBL] [Abstract][Full Text] [Related]
51. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
[TBL] [Abstract][Full Text] [Related]
52. [Analysis of the clinical characteristics and early warning model construction of severe/critical coronavirus disease 2019 patients].
Xu J; Zhao F; Han M; Ma L; Zhang T
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Apr; 32(4):401-406. PubMed ID: 32527341
[TBL] [Abstract][Full Text] [Related]
53. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
54. Combined predictive performance of age and neutrophilic percentage on admission for severe novel coronavirus disease 2019.
Chen Y; Zhi H; Zhang K; Zhu G; Liu L; Yan X; Cai Z; Zhao C; Hu Z
Int J Clin Pract; 2021 Jul; 75(7):e14257. PubMed ID: 33884718
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China.
Su Y; Ling Y; Ma Y; Tao L; Miao Q; Shi Q; Pan J; Lu H; Hu B
Biosci Trends; 2021 Jan; 14(6):408-414. PubMed ID: 33342929
[TBL] [Abstract][Full Text] [Related]
56. Vitamin C-An Adjunctive Therapy for Respiratory Infection, Sepsis and COVID-19.
Holford P; Carr AC; Jovic TH; Ali SR; Whitaker IS; Marik PE; Smith AD
Nutrients; 2020 Dec; 12(12):. PubMed ID: 33297491
[TBL] [Abstract][Full Text] [Related]
57. [Analysis on clinical study protocols of traditional Chinese medicine for coronavirus disease 2019].
Wang H; Jin XY; Pang B; Liu CX; Zheng WK; Yang FW; Pang WT; Zhang JH
Zhongguo Zhong Yao Za Zhi; 2020 Mar; 45(6):1232-1241. PubMed ID: 32281330
[TBL] [Abstract][Full Text] [Related]
58. Predictive role of clinical features in patients with coronavirus disease 2019 for severe disease.
Mo J; Liu J; Wu S; LÜ A; Xiao L; Chen D; Zhou Y; Liang L; Liu X; Zhao J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 May; 45(5):536-541. PubMed ID: 32879103
[TBL] [Abstract][Full Text] [Related]
59. Clinical and Epidemiological Characteristics of COVID-19 Patients in Chongqing China.
Yang A; Qiu Q; Kong X; Sun Y; Chen T; Zuo Y; Yuan D; Dai W; Zhou J; Peng A
Front Public Health; 2020; 8():244. PubMed ID: 32574309
[No Abstract] [Full Text] [Related]
60. Clinical characteristics and outcomes of critically ill patients with novel coronavirus infectious disease (COVID-19) in China: a retrospective multicenter study.
Xie J; Wu W; Li S; Hu Y; Hu M; Li J; Yang Y; Huang T; Zheng K; Wang Y; Kang H; Huang Y; Jiang L; Zhang W; Zhong M; Sang L; Zheng X; Pan C; Zheng R; Li X; Tong Z; Qiu H; Du B
Intensive Care Med; 2020 Oct; 46(10):1863-1872. PubMed ID: 32816098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
